drugset / Trial / NCT04551066

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

NCT04551066

Phase 3 Terminated 252 enrolled Incyte Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

Timeline

Start
2021-05-24
Primary completion
2023-08-03
Completion
2024-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Parsaclisib Small molecule Oral
Background Ruxolitinib Small molecule Oral